Blog
RSS FeedPosted by Michael Wonder on 25 Mar 2021
High cost patented drugs now account for 50% of sales
25 March 2021 - Federal Minister of Health tables the 2019 Annual Report of the Patented Medicine Prices Review Board ...
Posted by Michael Wonder on 18 Mar 2019
The impact of pharmaceutical rebates on patients’ drug expenditures
18 March 2019 - The drug-pricing landscape in Canada is complex, with 4 different agencies and each provincial, territorial and federal ...
Posted by Michael Wonder on 07 Dec 2018
Surviving niche busters: Main strategies employed by Canadian private insurers facing the arrival of high cost specialty drugs
6 December 2018 - The Canadian patchwork system of prescription drug coverage and the employer sponsored private health benefits group plans ...
Posted by Michael Wonder on 28 Jun 2018
High cost specialty drugs continue to dominate the new drug landscape
26 June 2018 - The Patented Medicine Prices Review Board, through the National Prescription Drug Utilisation Information System research initiative, ...
Posted by Michael Wonder on 04 Dec 2017
Brand name drug sales soar in Canada, while R&D sags
1 December 2017 - Patented drug industry disputes it's failing to invest enough into research and development. ...